Lysocin E Targeting Menaquinone in the Membrane of Mycobacterium tuberculosis Is a Promising Lead Compound for Antituberculosis Drugs
Year: 2022
Type: article
Abstract: activity against both drug-susceptible and drug-resistant Mycobacterium tuberculosis var. tuberculosis and dormant mycobacteria. Lysocin E is likely bound to menaquinone, causing M. tuberculosis membrane disruption, inhibition of oxygen consumption, and ATP synthesis. Thus, we have concluded that the high antituberculosis activity of lysocin E is attributable to its synergistic effects of membrane disruption and respiratory inhibition. The efficacy of lysocin E against intracellular M. tuberculosis in macrophages was lower than its potent activity against M. tuberculosis in culture medium, probably due to its low ability to penetrate cells, but its efficacy in mice was still superior to that of streptomycin. Our findings indicate that lysocin E is a promising lead compound for the development of a new tuberculosis drug that cures drug-resistant and latent tuberculosis in a shorter period.
DOI: 10.1128/aac.00171-22
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1326020628, Functional analysis of novel substances from food materials showing strong abilities of innate immunity stimulation, Elucidation of Molecular Mechanism of Mycobacterial Latency via Mycobacterial Membrane Vesicles, G3806304657, G4191322110, G4267848195, Expanding functional genomics of nontuberculous mycobacteria for establishing strategies for prevention, predictive diagnosis and drug development, Development of rapid diagnosis of drug sensitivity and optimal choice of chemotherapeutic regimen in MAC pulmonary disease by making use of TnSeq, Establishment of the therapeutic platform of MAC pulmonary disease by identifying essential genes covering the genetic diversity of clinical strains, 結核の発病予測向上と治療期間短縮を目指した生物学的要因の探索
OpenAlex ID: W4291786491
